Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study

Ming-Jang Chiu; Ta-Fu Chen; Chaur-Jong Hu; Sui-Hing Yan; Yu Sun; Bing-Hsien Liu; Yun-Tsui Chang; Che-Chuan Yang; Shieh-Yueh Yang

doi:10.1016/j.nano.2020.102182

Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study

Nanomedicine. 2020 Aug:28:102182. doi: 10.1016/j.nano.2020.102182. Epub 2020 Mar 25.

Authors

Ming-Jang Chiu¹, Ta-Fu Chen², Chaur-Jong Hu³, Sui-Hing Yan⁴, Yu Sun⁵, Bing-Hsien Liu⁶, Yun-Tsui Chang⁶, Che-Chuan Yang⁶, Shieh-Yueh Yang⁶

Affiliations

¹ Department of Neurology, National Taiwan University of Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan; Department of Psychology, College of Science, National Taiwan University, Taipei, Taiwan. Electronic address: mjchiu@ntu.edu.tw.
² Department of Neurology, National Taiwan University of Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
³ Department of Neurology, Taipei Medical University Shuang-Ho Hospital, New Taipei City, Taiwan.
⁴ Department of Neurology, Renai Branch, Taipei City Hospital, Taipei, Taiwan; Department of Neurology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
⁵ Department of Neurology, National Taiwan University of Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan.
⁶ MagQu Co., Ltd., New Taipei City, Taiwan.

PMID: 32222476
DOI: 10.1016/j.nano.2020.102182

Abstract

Blood-based biomarker assays of plasma β-amyloid (Aβ) and tau have the advantages of cost-effective and less invasive for the diagnosis of Alzheimer's disease (AD). We used two independent cohorts to cross-validate the clinical use of the nanoparticle-based immunomagnetic assay of plasma biomarkers to assist in the differential diagnosis of early AD. There were in total 160 subjects in the derivation cohort, and 242 in the validation cohort both containing controls, mild cognitive impairment due to AD and AD dementia diagnosed according to the 2011 NIA-AA guidelines. The cutoff value for plasma Aβ_1-42 (16.4 pg/ml) performed the best in differentiating between controls and patients with prodromal or clinical AD, with 92.5% for positive percent agreement (PPA), negative percent agreement (NPA), and overall rate of agreement (ORA). Aβ_1-42 × tau (642.58) was useful for separating patients with dementia and prodromal states of AD, with 84.9% PPA, 78.8% NPA and 83% ORA.

Keywords: Blood-based biomarkers; Immunomagnetic reduction assay; Mild cognitive impairment; Plasma Aβ(1–42); Plasma tau.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Alzheimer Disease / blood*
Alzheimer Disease / diagnosis*
Amyloid beta-Peptides / blood
Biomarkers / blood*
Cognitive Dysfunction / blood
Cognitive Dysfunction / diagnosis
Cross-Sectional Studies
Dementia / blood*
Dementia / diagnosis*
Diagnosis, Differential
Female
Humans
Immunoassay / methods*
Male
Middle Aged
Nanoparticles / chemistry*
tau Proteins / blood

Substances

Amyloid beta-Peptides
Biomarkers
tau Proteins